• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed

    1/12/21 3:51:22 PM ET
    $AMRH
    Semiconductors
    Technology
    Get the next $AMRH alert in real time by email
    SC 13G 1 tm212864d1_sc13g.htm SC 13G

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934

     

    (Amendment No. ___)*

     

    Enveric Biosciences, Inc.
    (Name of Issuer)
    Common Stock, $0.01 par value per share
    (Title of Class of Securities)
    29405E109
    (CUSIP Number)
    December 31, 2020
    (Date of Event which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ¨ Rule 13d-1(b)

     

    x Rule 13d-1(c)

     

    ¨ Rule 13d-1(d)

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

    SCHEDULE 13G

     

    CUSIP No. 29405E109  
    1 Names of Reporting Persons
    Pinches Abowitz
    2 Check the appropriate box if a member of a Group (see instructions)
    (a)  ¨
    (b)  ¨
    3 Sec Use Only
     
    4 Citizenship or Place of Organization
    New York

    Number of
    Shares
    Beneficially
    Owned by Each
    Reporting Person
    With:

    5 Sole Voting Power
    934,257
    6 Shared Voting Power
    0
    7 Sole Dispositive Power
    934,257
    8 Shared Dispositive Power
    0
    9 Aggregate Amount Beneficially Owned by Each Reporting Person
    934,257
    10 Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
    ¨
    11 Percent of class represented by amount in row (9)
    8.0% (1)
    12 Type of Reporting Person (See Instructions)
    IN
                 

    (1)Beneficial ownership calculated based on Rule 13d-3 and in reliance upon the information contained in the Issuer’s Form 8-K, filed by the Issuer with the U.S. Securities and Exchange Commission on January 12, 2021.

     

     Page 2 of 6 

     

     

    SCHEDULE 13G

     

    CUSIP No. 29405E109  
    1 Names of Reporting Persons
    TAF Group LLC
    2 Check the appropriate box if a member of a Group (see instructions)
    (a)  ¨
    (b)  ¨
    3 Sec Use Only
     
    4 Citizenship or Place of Organization
    New York

    Number of
    Shares
    Beneficially
    Owned by Each
    Reporting Person
    With:

    5 Sole Voting Power
    934,257
    6 Shared Voting Power
    0
    7 Sole Dispositive Power
    934,257
    8 Shared Dispositive Power
    0
    9 Aggregate Amount Beneficially Owned by Each Reporting Person
    934,257
    10 Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
    ¨
    11 Percent of class represented by amount in row (9)
    8.0% (2)
    12 Type of Reporting Person (See Instructions)
    PN
                 

    (2)Beneficial ownership calculated based on Rule 13d-3 and in reliance upon the information contained in the Issuer’s Form 8-K, filed by the Issuer with the U.S. Securities and Exchange Commission on January 12, 2021.

     

     Page 3 of 6 

     

     

    Item 1.

     

    (a)Name of Issuer: Enveric Biosciences, Inc.

     

    (b)Address of Issuer’s Principal Executive Offices: 4851 Tamiami Trail N, Suite 200, Naples, Florida 34103

     

    Item 2.

     

    (a)Name of Person Filing:

     

    Pinches Abowitz

    TAF Group LLC

     

    (b)Address of Principal Business Office or, if None, Residence: The address of the principal business office of each of the Reporting Persons is c/o TAF Group LLC, 1803 51st Street, Brooklyn, New York 11204.

     

    (c)Citizenship: See Item 4 on the cover page(s) hereto.

     

    (d)Title and Class of Securities: Common Stock, $0.01 par value per share

     

    (e)CUSIP No.: 29405E109

     

    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

     

    (a)¨ Broker or dealer registered under Section 15 of the Act;

     

    (b)¨ Bank as defined in Section 3(a)(6) of the Act;

     

    (c)¨ Insurance company as defined in Section 3(a)(19) of the Act;

     

    (d)¨ Investment company registered under Section 8 of the Investment Company Act of 1940;

     

    (e)¨ An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E);

     

    (f)¨ An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F);

     

    (g)¨ A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G);

     

    (h)¨ A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

     

    (i)¨ A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940;

     

    (j)¨ A non-U.S. institution in accordance with Rule 240.13d-1(b)(1)(ii)(J);

     

    (k)¨ Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with Rule 240.13d-1(b)(1)(ii)(J), please specify the type of institution: ____

     

     Page 4 of 6 

     

     

    Item 4.Ownership

     

    (a)Amount Beneficially Owned:    See Item 9 on the cover pages hereto.

     

    (b)Percent of Class: See Item 11 on the cover pages hereto.

     

    (c)Number of shares as to which such person has:

     

    (i)Sole power to vote or to direct the vote: See Item 5 on the cover pages hereto.

     

    (ii)Shared power to vote or to direct the vote: See Item 6 on the cover pages hereto.

     

    (iii)Sole power to dispose or to direct the disposition of: See Item 7 on the cover pages hereto.

     

    (iv)Shared power to dispose or to direct the disposition of: See Item 8 on the cover pages hereto.

     

    Item 5.Ownership of Five Percent or Less of a Class.

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following ¨.

     

    Item 6.Ownership of more than Five Percent on Behalf of Another Person.

     

    Not applicable.

     

    Item 7.Identification and classification of the subsidiary which acquired the security being reported on by the parent holding company or control person.

     

    Not applicable.

     

    Item 8.Identification and classification of members of the group.

     

    Not applicable.

     

    Item 9.Notice of Dissolution of Group.

     

    Not applicable.

     

    Item 10.Certifications.

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect other than activities solely in connection with a nomination under § 240.14a-11.

     

     Page 5 of 6 

     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Dated: January 12, 2021

     

      /s/ Pinches Abowitz
      Pinches Abowitz
       
       
      TAF GROUP LLC
       
       
      By: /s/ Pinches Abowitz
        Pinches Abowitz
        Managing Member

     

    The original statement shall be signed by each person on whose behalf the statement is filed or his authorized representative. If the statement is signed on behalf of a person by his authorized representative (other than an executive officer or general partner of this filing person), evidence of the representative's authority to sign on behalf of such person shall be filed with the statement, provided, however, that a power of attorney for this purpose which is already on file with the Commission may be incorporated by reference. The name and any title of each person who signs the statement shall be typed or printed beneath his signature.

     

    Attention: Intentional misstatements or omissions of fact constitute Federal criminal violations (See 18 U.S.C. 1001).

     

     Page 6 of 6 

     

    Get the next $AMRH alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AMRH

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $AMRH
    SEC Filings

    View All

    SEC Form 8-K filed

    8-K - Enveric Biosciences, Inc. (0000890821) (Filer)

    1/15/21 4:16:05 PM ET
    $AMRH
    Semiconductors
    Technology

    SEC Form 424B5 filed

    424B5 - Enveric Biosciences, Inc. (0000890821) (Filer)

    1/13/21 5:28:07 PM ET
    $AMRH
    Semiconductors
    Technology

    SEC Form 8-K/A filed

    8-K/A - Enveric Biosciences, Inc. (0000890821) (Filer)

    1/13/21 5:25:09 PM ET
    $AMRH
    Semiconductors
    Technology

    $AMRH
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Ameri Holdings Completes Spin-Off and Tender Offer, Changes Name to Enveric Biosciences and Begins Trading on the Nasdaq Under the Symbol "ENVB"

    NAPLES, Fla., Dec. 31, 2020 /PRNewswire/ -- Enveric Biosciences, Inc. (NASDAQ: ENVB) ("Enveric" or the "Company"), formerly AMERI Holdings, Inc. (NASDAQ: AMRH), a patient-centric biotechnology company endeavoring to enhance the lives of those who are adversely affected by the side effects of Cancer Treatments with novel cannabinoid medicines, announced the completion of the previously announced spin-off of the IT services business of the Company and the tender offer, whereby the Company purchased all of the outstanding common shares of Jay Pharma Inc. ("Jay Pharma") in exchange for shares of Company common stock, or if applicable, shares of Company preferred stock., and Jay Pharma became

    12/31/20 8:21:00 AM ET
    $AMRH
    Semiconductors
    Technology

    AMERI Holdings Announces 1-for-4 Reverse Stock Split

    ATLANTA, Dec. 30, 2020 /PRNewswire/ -- AMERI Holdings, Inc. (NASDAQ: AMRH) ("Ameri", the "Company"), announced a 1-for-4 reverse split of its common stock, effective as of 4:02 pm Eastern Time, December 30, 2020 (the "Reverse Stock Split"). As previously announced, at the special meeting of stockholders held on December 29, 2020, Ameri's stockholders approved all proposals to complete the proposed tender offer (the "Offer"), whereby Ameri will purchase all of the outstanding common shares of Jay Pharma Inc. ("Jay Pharma") in exchange for shares of Ameri common stock, or if applicable, shares of Ameri preferred stock, at the exchange ratio set forth in the Tender Offer Support Agreement a

    12/30/20 12:59:00 PM ET
    $AMRH
    Semiconductors
    Technology

    AMERI Holdings' Stockholders Approve All Proposals To Complete Tender Offer For Jay Pharma Shares

    ATLANTA, Dec. 29, 2020 /PRNewswire/ -- AMERI Holdings, Inc. (NASDAQ: AMRH) ("Ameri", the "Company"), announced the voting results of the Special Meeting of stockholders that was held today. Based on the report from the Inspector of Elections, Ameri obtained sufficient votes for each proposal required to complete the previously announced proposed tender offer (the "Offer"), whereby Ameri will purchase all of the outstanding common shares of Jay Pharma Inc. ("Jay Pharma") in exchange for shares of Ameri common stock, or if applicable, shares of Ameri preferred stock, at the exchange ratio set forth in the Tender Offer Support Agreement and Termination of Amalgamation Agreement dated August

    12/29/20 10:10:00 AM ET
    $AMRH
    Semiconductors
    Technology

    $AMRH
    Leadership Updates

    Live Leadership Updates

    View All

    AMERI Holdings' Stockholders Approve All Proposals To Complete Tender Offer For Jay Pharma Shares

    ATLANTA, Dec. 29, 2020 /PRNewswire/ -- AMERI Holdings, Inc. (NASDAQ: AMRH) ("Ameri", the "Company"), announced the voting results of the Special Meeting of stockholders that was held today. Based on the report from the Inspector of Elections, Ameri obtained sufficient votes for each proposal required to complete the previously announced proposed tender offer (the "Offer"), whereby Ameri will purchase all of the outstanding common shares of Jay Pharma Inc. ("Jay Pharma") in exchange for shares of Ameri common stock, or if applicable, shares of Ameri preferred stock, at the exchange ratio set forth in the Tender Offer Support Agreement and Termination of Amalgamation Agreement dated August

    12/29/20 10:10:00 AM ET
    $AMRH
    Semiconductors
    Technology